Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-17. Numbers and descriptions here follow the published literature rather than marketing material.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
=== STRACO === An elite force named Specially Trained Armed Company or STRACO has been created to combat insurgency & terrorism, posted in West Zone to fight Maoist guerrillas. WBP is raising another new "Counter Insurgency" force on the line of Gray Hound Special Force of Andhra Pradesh Police.
Rhodium (from Greek: ῥόδον rhodon, meaning 'rose') was discovered in 1803 by William Hyde Wollaston, soon after he discovered palladium. He used crude platinum ore presumably obtained from South America. His procedure started by dissolving the ore in aqua regia, precipitating the platinum as ammonium chloroplatinate by adding ammonium chloride (NH4Cl). Adding zinc precipitated a mixture of copper, lead, palladium, and rhodium. Dilute nitric acid dissolved the copper and lead. Dissolving the remainder in aqua regia again and adding sodium chloride, the solution was evaporated to yield rose-red Na3[RhCl6]·nH2O. After extraction with hot ethanol, additional zinc displaced the rhodium in the ionic compound, releasing the rhodium as free metal. For decades, the rare element had only minor applications; for example, by the turn of the century, rhodium-containing thermocouples were used to measure temperatures up to 1800 °C. They have exceptionally good stability in the temperature range of 1300 to 1800 °C. The first major application was electroplating for decorative uses and as corrosion-resistant coating. The introduction of the three-way catalytic converter by Volvo in 1976 increased the demand for rhodium. The previous catalytic converters used platinum or palladium, while the three-way catalytic converter used rhodium to reduce the amount of NOx in the exhaust.
Altitude related – Polycythemia can be a normal adaptation to living at high altitudes (see altitude sickness). Many athletes train at high altitude to take advantage of this effect, which can be considered a legal form of blood doping, although the efficacy of this strategy is unclear. Hypoxic disease-associated – for example, in cyanotic heart disease where blood oxygen levels are reduced significantly; in hypoxic lung disease such as COPD; in chronic obstructive sleep apnea; conditions that reduce blood flow to the kidney e.g. renal artery stenosis. Chronic carbon monoxide poisoning (which can be present in heavy smokers) and rarely methemoglobinemia can also impair oxygen delivery. Genetic – Heritable causes of secondary polycythemia include abnormalities in hemoglobin oxygen release, which results in a greater inherent affinity for oxygen than normal adult hemoglobin and reduces oxygen delivery to tissues. Conditions where the secondary polycythemia is not caused by physiologic adaptation, and occurs irrespective of body needs include:
Sources: en.wikipedia.org
RLi + S → RSLi RSLi + HCl → RSH + LiCl Phenols can be converted to the thiophenols via rearrangement of their O-aryl dialkylthiocarbamates. Thiols are prepared by reductive dealkylation of sulfides, especially benzyl derivatives and thioacetals. Thiophenols are produced by S-arylation or the replacement of diazonium leaving group with sulfhydryl anion (SH−):
==== Cognitive performance ==== In 2015, a systematic review and a meta-analysis of high quality clinical trials found that, when used at low (therapeutic) doses, amphetamine produces modest yet unambiguous improvements in cognition, including working memory, long-term episodic memory, inhibitory control, and some aspects of attention, in normal healthy adults; these cognition-enhancing effects of amphetamine are known to be partially mediated through the indirect activation of both dopamine D1 receptor and α2-adrenergic receptor in the prefrontal cortex. A systematic review from 2014 found that low doses of amphetamine also improve memory consolidation, in turn leading to improved recall of information. Therapeutic doses of amphetamine also enhance cortical network efficiency, an effect which mediates improvements in working memory in all individuals. Amphetamine and other ADHD stimulants also improve task saliency (motivation to perform a task) and increase arousal (wakefulness), in turn promoting goal-directed behavior. Stimulants such as amphetamine can improve performance on difficult and boring tasks and are used by some students as a study and test-taking aid. Based upon studies of self-reported illicit stimulant use, 5–35% of college students use diverted ADHD stimulants, which are primarily used for enhancement of academic performance rather than as recreational drugs. However, high amphetamine doses that are above the therapeutic range can interfere with working memory and other aspects of cognitive control.
== Radioactive, primordial, and stable isotopes == Some isotopes/nuclides are radioactive, and are therefore called radioisotopes or radionuclides, whereas others have never been observed to decay radioactively and are called stable isotopes or stable nuclides. For example, 14C is a radioactive form of carbon, while 12C and 13C are stable isotopes. There are about 339 naturally occurring nuclides on Earth, of which 286 are primordial nuclides, meaning that they have existed since the Solar System's formation. Primordial nuclides include 35 nuclides with very long half-lives (over 100 million years) and 251 that are considered "stable nuclides", as they have not been observed to decay. In most cases, if an element has stable isotopes, those isotopes predominate in the elemental abundance found on Earth and in the Solar System. However, in the cases of three elements (tellurium, indium, and rhenium) the most abundant isotope found in nature is actually one (or two) extremely long-lived radioisotope(s) of the element, despite these elements having one or more stable isotopes. Theory predicts that many apparently "stable" nuclides are radioactive, with extremely long half-lives (discounting the possibility of proton decay, which would make all nuclides ultimately unstable). Some stable nuclides are in theory energetically susceptible to other known forms of decay, such as alpha decay or double beta decay, but no decay products have yet been observed, and so these isotopes are said to be "observationally stable".
Sources: en.wikipedia.org
== External links == Media related to Ayahuasca at Wikimedia Commons The dictionary definition of ayahuasca at Wiktionary Ayahuasca - PsychonautWiki Ayahuasca - Erowid What is Ayahuasca? - Tripsitter The Ayahuasca Experience: A Pilgrimage to the Spirit - Double Blind Magazine
The king cobra (Ophiophagus hannah) is a species complex of snakes endemic to Asia. With an average length of 3.18 to 4 m (10.4 to 13.1 ft) and a record length of 5.85 m (19.2 ft), it is the world's longest venomous snake and among the heaviest. Under the genus Ophiophagus, it is not phylogenetically a true cobra despite its common name and some resemblance. Spanning from the Indian subcontinent through Southeastern Asia to Southern China, the king cobra is widely distributed albeit not commonly seen. Individuals have diversified colouration across its habitats, from black with white strips to unbroken brownish grey, although after taxonomic re-evaluation, it is no longer the sole member of its genus but is now a species complex; these differences in pattern and other aspects may cause the genus to be split into at least four species, spread across its large geographic range. It chiefly hunts other snakes, including those of its own kind, although other lizards and rodents are also occasional prey. This is the only ophidian that constructs an above-ground nest for its eggs, which are purposefully and meticulously gathered and protected by the female throughout the incubation period. Typical threat display of this elapid includes neck-flap spreading, head raising, hissing and sometimes charging. Capable of striking at a considerable range and height with an immense venom yield, envenomation from this species may induce rapid onset of neurotoxic and cytotoxic symptoms, requiring prompt antivenom administration.
Healthy diet (a diet with limited refined carbohydrates, added sugars, trans fats, as well as limited intake of sodium and total calories) Physical fitness (30–45 minutes of cardiovascular exercise per day, 3–5 days a week) Weight loss by as little as 5–10 percent may have a significant impact on overall health
Knowing that there are a few studies about the genomic data of the tyrosinase gene, there are only a handful of studies on the mutations in albino amphibians. Miura et al. (2018) investigates the amino acid mutations in the tyrosinase gene in three albino frogs: Pelophylax nigromaculatus (pond frog), Glandirana rugosa (wrinkled frog) and Fejervarya kawamurai (rice frog). In total, five different populations were studied of which three were P. nigromaculatus and one each of G. rugosa and F. kawamurai. In two of the three P. nigromaculatus populations, there was a frameshift mutation because of the insertion of a thymine within exons 1 and 3, and the third population lacked three nucleotides that encoded a Lysine in exon 1. The population of G. rugosa had a missense mutation where there was an amino acid substitution from a Glycine to Aspartic acid, and the mutation of F. kawamurai was also an amino acid substitution from Glycine to Arginine. The mutation for G. rugosa and F. kawamurai occurs in exons 1 and 3. The mutations of the third population of P. nigromaculatus, and the mutations of G. rugosa and F. kawamurai occurred in areas that are highly conserved among vertebrates which could result in a dysfunctional tyrosinase gene.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.